

# Elizabeth A Shephard

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9529377/elizabeth-a-shephard-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

2,427

citations

28

h-index

49

g-index

65

ext. papers

2,698

ext. citations

5.4

avg, IF

4.97

L-index

#	Paper	IF	Citations
62	Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. <i>Nature Genetics</i> , <b>1997</b> , 17, 491-4	36.3	216
61	A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. <i>Computational and Structural Biotechnology Journal</i> , <b>2016</b> , 14, 135-53	6.8	184
60	Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. <i>Drug Metabolism and Disposition</i> , <b>2016</b> , 44, 1839-1850	4	181
59	Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 117-30		137
58	The molecular biology of the flavin-containing monooxygenases of man. <i>Chemico-Biological Interactions</i> , <b>1995</b> , 96, 17-32	5	125
57	Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. <i>Biochemical Pharmacology</i> , <b>2001</b> , 62, 777-86	6	103
56	Flavin-containing monooxygenases: mutations, disease and drug response. <i>Trends in Pharmacological Sciences</i> , <b>2008</b> , 29, 294-301	13.2	101
55	The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 30599-607	5.4	100
54	Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). <i>Biochemical Pharmacology</i> , <b>2004</b> , 68, 73-83	6	91
53	Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 12822-6	5.4	82
52	Trimethylaminuria and a human FMO3 mutation database. <i>Human Mutation</i> , <b>2003</b> , 22, 209-13	4.7	80
51	Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. <i>Biochemical Journal</i> , <b>2001</b> , 355, 71-78	3.8	79
50	Drug metabolism by flavin-containing monooxygenases of human and mouse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 167-181	5.5	59
49	Maintenance and induction in co-cultured rat hepatocytes of components of the cytochrome P450-mediated mono-oxygenase. <i>Biochemical Pharmacology</i> , <b>1993</b> , 45, 1583-91	6	57
48	Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. <i>Biochemical Journal</i> , <b>2001</b> , 355, 71-8	3.8	55
47	Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odour syndrome. <i>Pharmacogenetics and Genomics</i> , <b>2000</b> , 10, 799-807		55
46	Structural organization of the human flavin-containing monooxygenase 3 gene (FMO3), the favored candidate for fish-odor syndrome, determined directly from genomic DNA. <i>Genomics</i> , <b>1997</b> , 46, 260-7	4.3	47

45	Genetic polymorphisms of flavin-containing monooxygenase (FMO). <i>Drug Metabolism Reviews</i> , <b>2002</b> , 34, 523-32	7	46
44	Quantification of cytochrome P450 reductase gene expression in human tissues. <i>Archives of Biochemistry and Biophysics</i> , <b>1992</b> , 294, 168-72	4.1	44
43	A novel mutation in the flavin-containing monooxygenase 3 gene, FM03, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy. <i>Pharmacogenetics and Genomics</i> , <b>2000</b> , 10, 439-51		39
42	Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. <i>Hepatology</i> , <b>1992</b> , 16, 682-7	11.2	38
41	The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 877-86	1.9	37
40	Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 178-86	4	36
39	The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. <i>Biochemical Pharmacology</i> , <b>2015</b> , 96, 267-77	6	32
38	Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. <i>Mutation Research - Reviews in Mutation Research</i> , <b>2006</b> , 612, 165-171	7	32
37	Cloning and sequence analysis of a rat liver cDNA coding for a phenobarbital-inducible microheterogenous cytochrome P-450 variant: regulation of its messenger level by xenobiotics. <i>Gene</i> , <b>1983</b> , 26, 41-52	3.8	31
36	The phenotype of a flavin-containing monooxygenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance. <i>Biochemical Pharmacology</i> , <b>2014</b> , 90, 88-95	6	28
35	Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease. <i>Xenobiotica</i> , <b>2020</b> , 50, 19-33	2	28
34	Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 827-39	1.9	27
33	Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse. <i>Biochemical Journal</i> , <b>2007</b> , 406, 491-9	3.8	26
32	Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine -oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis. <i>Drug Metabolism and Disposition</i> , <b>2018</b> , 46, 20-25	4	24
31	Clinical utility gene card for: Trimethylaminuria - update 2014. <i>European Journal of Human Genetics</i> , <b>2015</b> , 23,	5.3	20
30	Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 289-99	1.9	20
29	Transfection of liver in vivo by biolistic particle delivery: its use in the investigation of cytochrome P450 gene regulation. <i>Molecular Biotechnology</i> , <b>2002</b> , 20, 145-51	3	18
28	Flavin-Containing Monooxygenase 1 Catalyzes the Production of Taurine from Hypotaurine. <i>Drug Metabolism and Disposition</i> , <b>2020</b> , 48, 378-385	4	17

27	Identification of Flavin-Containing Monooxygenase 5 (FMO5) as a Regulator of Glucose Homeostasis and a Potential Sensor of Gut Bacteria. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 982-989 <sup>4</sup>		17
26	Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 77, 839-51	3.8	17
25	The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 1083-94	5.5	15
24	A highly sensitive liquid chromatography electrospray ionization mass spectrometry method for quantification of TMA, TMAO and creatinine in mouse urine. <i>MethodsX</i> , <b>2017</b> , 4, 310-319	1.9	12
23	Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse. <i>Pharmaceuticals</i> , <b>2012</b> , 5, 1147-59	5.2	12
22	Clinical utility gene card for: trimethylaminuria. <i>European Journal of Human Genetics</i> , <b>2012</b> , 20,	5.3	10
21	Deletion of genes from the mouse genome using Cre/loxP technology. <i>Methods in Molecular Biology</i> , <b>2006</b> , 320, 307-19	1.4	8
20	Metabolic Biomarkers of Ageing in C57BL/6J Wild-Type and Flavin-Containing Monooxygenase 5 (FMO5)-Knockout Mice. <i>Frontiers in Molecular Biosciences</i> , <b>2018</b> , 5, 28	5.6	7
19	A novel mutation in the flavin-containing monooxygenase 3 gene (FMO3) of a Norwegian family causes trimethylaminuria. <i>Molecular Genetics and Metabolism</i> , <b>2009</b> , 98, 198-202	3.7	6
18	Isolation and Culture of Mouse Hepatocytes: Gender-Specific Gene Expression Responses to Chemical Treatments. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1250, 3-12	1.4	6
17	Microinjection of targeted embryonic stem cells and establishment of knockout mouse lines for Fmo genes. <i>Methods in Molecular Biology</i> , <b>2006</b> , 320, 329-41	1.4	6
16	Endogenous Roles of Mammalian Flavin-Containing Monooxygenases. <i>Catalysts</i> , <b>2019</b> , 9, 1001	4	5
15	Pharmacogenetic testing in the UK clinical setting. <i>Lancet, The</i> , <b>2013</b> , 381, 1903	4.0	3
14	Pyruvate-induced long-term maintenance of glutathione s-transferase in rat hepatocyte cultures. <i>ATLA Alternatives To Laboratory Animals</i> , <b>2001</b> , 29, 335-46	2.1	2
13	Regulation of cytochrome P4502B2 gene expression. <i>Biochemical Society Transactions</i> , <b>1994</b> , 22, 125S	5.1	2
12	The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care. <i>Drug Metabolism and Personalized Therapy</i> , <b>2016</b> , 31, 91-6	2	1
11	Transfection of Primary Cultures of Rat Hepatocytes. <i>Methods in Molecular Biology</i> , <b>2006</b> , 320, 273-282	1.4	1
10	Expression in a baculovirus system of a cDNA encoding human CYP2A6. <i>Biochemical Society Transactions</i> , <b>1994</b> , 22, 122S	5.1	1

- 9 FMO1 catalyzes the production of taurine from hypotaurine 1
- 8 Flavin-containing monooxygenases: new structures from old proteins. *Nature Structural and Molecular Biology*, **2020**, 27, 3-4 17.6 0
- 7 Immortalized hepatocytes from transgenic mice. *Biochemical Society Transactions*, **1997**, 25, 42S 5.1
- 6 Effects of the Anticonvulsant, Valproate, on the Expression of Components of the Cytochrome-P-450-Mediated Monooxygenase System and Glutathione S-Transferases. *FEBS Journal*, **2008**, 231, 337-343
- 5 Expression of Recombinant Flavin-Containing Monooxygenases in a Baculovirus/Insect Cell System. *Methods in Molecular Biology*, **2006**, 320, 39-59 1.4
- 4 Determination of Cellular Localization of Expression of Flavin-Containing Monooxygenase Genes in Mouse Tissues by In Situ Hybridization. *Methods in Molecular Biology*, **2006**, 320, 295-305 1.4
- 3 Microinjection of Targeted Embryonic Stem Cells and Establishment of Knockout Mouse Lines for Fmo Genes. *Methods in Molecular Biology*, **2006**, 320, 329-341 1.4
- 2 Deletion of Genes From the Mouse Genome Using Cre/loxP Technology. *Methods in Molecular Biology*, **2006**, 320, 307-319 1.4
- 1 Cell systems capable of sustaining phenobarbital induction by CYP2B genes. *Biochemical Society Transactions*, **1994**, 22, 120S 5.1